HKG:1541

4 stories mentioning HKG:1541Updated 25d ago

Every FINWIRES story that references HKG:1541, newest first.

ImmuneOnco Biopharma Doses First Patient in Phase 2/3 IgG4 Disease Trial

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient has been dosed in a Phase 2/3 clinical trial of its lead drug candidate IMM0306 for the treatment of IgG4-related disease, according to a Friday Hong Kong bourse filing.The trial will evaluate the efficacy of IMM0306 in reducing the risk of disease relapse, with secondary endpoints including safety, tolerability, pharmacokinetics and immunogenicity.Shares of the biopharmaceutical firm were up nearly 4% in midday trade on Friday.

HKG:1541

Asia45d ago

ImmuneOnco to Trim Stake in ImmuneCare via Jiaxing Changxin Deal

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) will lower its stake in ImmuneCare Biopharmaceutical (Shanghai) under a capital increase agreement with the latter's employee shareholding platform.Specifically, Jiaxing Changxin will subscribe for shares worth 325,000 yuan of the metabolic and rare disease-focused drug development company, according to a filing late Thursday.Upon deal completion, the Hong Kong-listed clinical-stage biotechnology company will own 80% of ImmuneCare, down from 93.0% due to dilution, while Jiaxing Changxin will hold the remaining 20%.

HKG:1541

Asia47d ago

ImmuneOnco Biopharm Invests HK$88 Million in Wealth Management Product

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) agreed to invest HK$87.5 million in a wealth management product offered by Vital Ventures, according to a Wednesday Hong Kong bourse filing.The cash management fund is expected to generate an annualized return of 1.5% to 4.5% and invests in assets including cash, bank deposits, certificates of deposit, and short-term U.S. Treasury bonds.The company said the subscription will be funded by surplus cash reserves and is intended to improve capital utilization and generate additional income from idle funds.

HKG:1541

Asia76d ago

ImmuneOnco Doses First Patient in IMM0306 Drug Trial; Shares Fall 3%

ImmuneOnco Biopharmaceuticals (HKG:1541) said it dosed the first patient in the phase 2 trial of IMM0306 for the treatment of systemic lupus erythematosus, according to a Tuesday filing with the Hong Kong bourse.The firm's shares fell 3% in morning trade Wednesday.The company plans to enroll 90 patient in the trial, it said.

HKG:1541

Track with the FINWIRES app suite

FolioX

Track HKG:1541 in your portfolio

WheelAI

Analyze HKG:1541 options with the wheel strategy

StockInsider

See market sentiment on HKG:1541